Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



An Indirect Sign of Good Things to Come

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

As stock-moving events go for biotechs, getting the EU to sign off on the manufacturing facility doesn't rank very high. Honestly, I can't even remember seeing a biotech ever issuing a press release about it.

Yet Alexza Pharmaceuticals (Nasdaq: ALXA  ) was up as much as 7% today on just that news, before trailing off later in the day. The company announced -- in a press release -- that it received its EU Certificate of GMP Compliance of a Manufacturer. That's the official way of saying it can make its inhaled antipsychotic Adasuve and sell it in the EU, assuming it gains approval. That decision from the EU regulatory agency isn't expected until at least December.

So what's the big deal? While an approval is the real stock-moving event, clearing up manufacturing issues seem to be the key to getting Adasuve on the market.

In May, the Food and Drug Administration rejected the drug, and management said manufacturing issues were the only major problem the agency had with Adasuve. Alexza already resubmitted for approval and expects a new ruling by the FDA on or before Dec. 21.

If one regulatory body has signed off on the manufacturing of the drug, it's certainly a good sign that the FDA will do the same. Just keep in mind that the agencies don't always move in lockstep. There are plenty of examples of drugs that are approved in the E.U. and not in the U.S.: Merck's (NYSE: MRK  ) Cordaptive, InterMune's (Nasdaq: ITMN  ) Esbriet, and Sanofi's (NYSE: SNY  ) Acomplia, just to name a few.

Generally speaking, it's easier to get a drug approved in the EU than the U.S., but the stateside market is more important to Alexza because it has the full rights to the drug here but licensed out the European rights to Grupo Ferrer.

Unfortunately, manufacturing remains mostly a black box to investors. The EU manufacturing approval shines a little light on the box, but investors won't be certain that there isn't anything else hiding in the box until the FDA rules at the end of the year. Expect a much bigger jump than the one we saw today if the FDA approves the drug this time around.

The biggest binary event, the presidential election, is around the corner. Check out the Fool's new free report, "These Stocks Could Skyrocket After the 2012 Presidential Election," where you'll get ideas for companies that can benefit from each candidate's platform. Get your free copy.

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1992752, ~/Articles/ArticleHandler.aspx, 10/27/2016 1:04:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,202.49 3.16 0.02%
S&P 500 2,137.53 -1.90 -0.09%
NASD 5,230.47 -19.79 -0.38%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ALXA.DL $0.00 Down +0.00 +0.00%
Alexza Pharmaceuti… CAPS Rating: **
ITMN.DL $0.00 Down +0.00 +0.00%
InterMune CAPS Rating: **
MRK $61.66 Up +0.79 +1.30%
Merck and Co. CAPS Rating: ****
SNY $37.79 Up +0.73 +1.96%
Sanofi CAPS Rating: *****